Current through Register Vol. 63, No. 11, November 1, 2024
Section 333-116-0670 - Training for Imaging and Localization StudiesExcept as provided in OAR 333-116-0740, the licensee shall require an authorized user of unsealed byproduct material for the uses authorized under OAR 333-116-0320 to be a physician who:
(1) Is certified by a medical specialty board whose certification process has been recognized by the U.S. Nuclear Regulatory Commission or an Agreement State. The names of board certifications that have been recognized by the U.S. Nuclear Regulatory Commission or an Agreement State are posted on the NRC's Medical Uses Licensee Toolkit webpage. To have its certification process recognized, a specialty board shall require all candidates for certification to:(a) Complete 700 hours of training and experience in basic radionuclide handling techniques and radiation safety applicable to the medical use of unsealed byproduct material for imaging and localization studies as described in subsection (3)(a) through paragraph (2)(b)(G) of this rule; and(b) Pass an examination administered by diplomats of the specialty board, which assesses knowledge and competence in radiation safety, radionuclide handling and quality control; or(2) Is an authorized user under OAR 333-116-0680 and meets the requirements in OAR 333-116-0670(3)(b)(G) or equivalent U.S. Nuclear Regulatory Commission or Agreement State requirements; or(3) Has completed 700 hours of training and experience, including a minimum of 80 hours of classroom and laboratory training in basic radionuclide handling techniques applicable to the medical use of unsealed byproduct material for imaging and localization studies. (a) The training and experience must include at a minimum classroom and laboratory training in the following areas: (A) Radiation physics and instrumentation;(B) Radiation protection;(C) Mathematics pertaining to the use and measurement of radioactivity;(D) Chemistry of byproduct material for medical use; and(E) Radiation biology; and(b) Work experience, under the supervision of an authorized user, who meets the requirements in this rule or OAR 333-116-0670, 333-116-0680, 333-116-0740 and 333-116-0670(3)(b)(G) or equivalent U.S. Nuclear Regulatory Commission or Agreement State requirements. An authorized nuclear pharmacist who meets the requirements in OAR 333-116-0740 or 333-116-0910 may provide the supervised work experience for paragraph (3)(b)(G) of this rule. Work experience must involve: (A) Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys;(B) Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters;(C) Calculating, measuring, and safely preparing patient or human research subject dosages;(D) Using administrative controls to prevent a medical event involving the use of unsealed byproduct material;(E) Using procedures to safely contain spilled radioactive material and using proper decontamination procedures;(F) Administering dosages of radioactive drugs to patients or human research subjects; and(G) Eluting generator systems appropriate for preparation of radiopharmaceutical drugs for imaging and localization studies, measuring and testing the eluate for radionuclide purity, and processing the eluate with reagent kits to prepare labeled radiopharmaceutical drugs; and(4) Has obtained written attestation that the individual has satisfactorily completed the requirements in section (3) of this rule and is able to independently fulfill the radiation safety-related duties as an authorized user for the medical uses authorized under OAR 333-116-0300 and 333-116-0320. The attestation must be obtained from either: (a) A preceptor authorized user who meets the requirements in OAR 333-116-0740, 333-116-0670 or 333-116-0680 and paragraph (3)(b)(G) of this rule or equivalent U.S. Nuclear Regulatory Commission or Agreement State requirements; or(b) A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in OAR 333-116-0740, 333-116-0670, or 333-116-0680 and paragraph (3)(b)(G) of this rule or equivalent Agreement State requirements, and concurs with the attestation provided by the residency program director. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in section (3) of this rule.Or. Admin. Code § 333-116-0670
HD 1-1991, f. & cert. ef. 1-8-91; PH 3-2003, f. & cert. ef. 3-27-03; PH 31-2004(Temp), f. & cert. ef. 10-8-04 thru 4-5-05; PH 36-2004, f. & cert. ef. 12-1-04; PH 12-2006, f. & cert. ef. 6-16-06; PH 4-2007, f. & cert. ef. 3-1-07; PH 14-2008, f. & cert. ef. 9-15-08; PH 4-2010, f. & cert. ef. 2-16-10; PH 10-2011, f. 9-30-11, cert. ef. 10-1-11; PH 4-2013, f. & cert. ef. 1-29-13; PH 65-2018, minor correction filed 02/01/2018, effective 2/1/2018; PH 81-2021, amend filed 11/19/2021, effective 11/23/2021Statutory/Other Authority: ORS 453.635
Statutes/Other Implemented: ORS 453.605 - 453.807